Zacks Research Has Positive Estimate for Imunon Q3 Earnings

Imunon, Inc. (NASDAQ:IMNN) – Equities research analysts at Zacks Research increased their Q3 2026 earnings estimates for Imunon in a research report issued to clients and investors on Wednesday, August 19th. Zacks Research analyst D. Bautz now anticipates that the company will earn ($0.56) per share for the quarter, up from their previous forecast of ($0.87). The consensus estimate for Imunon’s current full-year earnings is ($2.63) per share. Zacks Research also issued estimates for Imunon’s Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.47) EPS, FY2027 earnings at ($2.01) EPS and FY2028 earnings at ($1.85) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

Imunon Stock Performance

Imunon stock opened at $1.58 on Friday. The firm has a 50 day simple moving average of $1.75 and a 200-day simple moving average of $2.46. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.82 and a quick ratio of 1.82. The stock has a market capitalization of $8.86 million, a PE ratio of -0.41 and a beta of 1.97. Imunon has a 12-month low of $1.47 and a 12-month high of $6.96.

Imunon (NASDAQ:IMNN) last released its earnings results on Tuesday, August 11th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.33.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Imunon stock. Armistice Capital LLC acquired a new stake in shares of Imunon, Inc. (NASDAQ:IMNN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned about 8.69% of Imunon as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.